Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis

Eur Urol. 2016 Dec;70(6):1082-1083. doi: 10.1016/j.eururo.2016.05.040. Epub 2016 Jun 13.

Authors

Maria I Carlo¹, Darren R Feldman²

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: feldmand@mskcc.org.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Carcinoma, Renal Cell*
Humans
Kidney Failure, Chronic
Kidney Neoplasms*
Nivolumab

Substances

Antibodies, Monoclonal
Nivolumab

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States